CDKN2A and astrocytoma (excluding glioblastoma): Our findings are consistent with literature, since we report CDKN2A deletions in 28 from 63 cases (44.4%), with significantly higher frequency of both heterozygous and homozygous deletion in astrocytomas (p ≤ 0.0001 and p = 0.006 respectively).